VISENTIN, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.258
EU - Europa 1.120
AS - Asia 989
OC - Oceania 6
AF - Africa 3
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.381
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.250
IT - Italia 545
CN - Cina 497
SG - Singapore 371
FI - Finlandia 102
SE - Svezia 101
DE - Germania 96
FR - Francia 95
GB - Regno Unito 82
IN - India 43
VN - Vietnam 41
NL - Olanda 26
IE - Irlanda 20
RU - Federazione Russa 9
UA - Ucraina 9
CA - Canada 8
JP - Giappone 7
PH - Filippine 7
ES - Italia 6
PL - Polonia 6
AU - Australia 5
IL - Israele 5
RO - Romania 4
BG - Bulgaria 3
HK - Hong Kong 3
KR - Corea 3
AT - Austria 2
CH - Svizzera 2
DK - Danimarca 2
EU - Europa 2
GR - Grecia 2
LV - Lettonia 2
PK - Pakistan 2
TR - Turchia 2
TW - Taiwan 2
ZA - Sudafrica 2
AM - Armenia 1
BR - Brasile 1
EC - Ecuador 1
EE - Estonia 1
HR - Croazia 1
ID - Indonesia 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SA - Arabia Saudita 1
UY - Uruguay 1
Totale 8.381
Salva come PNG Salva come JPEG
Città #
Fairfield 1.175
Ashburn 555
Woodbridge 518
Chandler 467
Seattle 455
Houston 435
Cambridge 411
Wilmington 303
Ann Arbor 283
Singapore 279
Boardman 196
Padova 175
Santa Clara 154
San Diego 136
Beijing 113
Princeton 97
Medford 94
Guangzhou 72
Helsinki 72
Des Moines 66
New York 53
Roxbury 43
Dong Ket 38
Nanjing 37
Shanghai 26
Shenyang 23
London 22
Milan 22
Jinan 20
Rome 19
Los Angeles 18
Pune 18
Dallas 17
Dublin 14
Lappeenranta 12
Redwood City 12
Amsterdam 11
Nanchang 11
Tianjin 11
Hebei 10
Ogden 9
Cagliari 8
Hangzhou 8
Taiyuan 8
Washington 8
Falls Church 7
Kharkiv 7
Paris 7
Perugia 7
Regensburg 7
Venice 7
Verona 7
Cassano D'adda 6
Changsha 6
Fuzhou 6
Phoenix 6
Taizhou 6
Chicago 5
Frankfurt am Main 5
Genoa 5
Haikou 5
Kilburn 5
San Antonio 5
San Vito di Leguzzano 5
Baltimore 4
Bologna 4
Hefei 4
Jiaxing 4
Leeds 4
L’Aquila 4
Miami 4
Moscow 4
Pignone 4
Selvazzano Dentro 4
Zhengzhou 4
Baotou 3
Brendola 3
Caprino Veronese 3
Chiswick 3
Florence 3
Ho Chi Minh City 3
Homburg 3
Kolkata 3
Kunming 3
Naples 3
North York 3
Nürnberg 3
Pagadian 3
Parma 3
Redmond 3
Rockville 3
Salsomaggiore Terme 3
Sofia 3
Sydney 3
Tokyo 3
Tver 3
Vergiate 3
'Omer 2
Acton 2
Afragola 2
Totale 6.764
Salva come PNG Salva come JPEG
Nome #
Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL 199
Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo 197
HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia 172
Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells 168
Role of miR-15a/miR-16-1 and TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia 155
The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma 155
Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients 153
Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia 152
Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins 145
Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia 139
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. 136
Aberrant expression of CD10 and BCL6 in mantle cell lymphoma 134
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 134
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases 133
Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. 132
Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia 129
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia 129
Anti-sulfatide/galactocerebroside antibodies in immunoglobulin M paraproteinemic neuropathies 128
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival 127
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations and clinical impact 127
Expression and function of protein kinase CK2 in Hodgkin lymphoma 126
Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole. 124
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome 123
p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes 118
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments 118
In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment 116
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia 115
Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia 114
Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-MAG antibody polyneuropathy 113
Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients 112
Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine 110
CX-4945, a selective inhibitor of casein kinase 2, synergizes with B cell receptor signaling inhibitors in inducing diffuse large B cell lymphoma cell death 109
p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape 100
Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy 98
Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases 98
Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia 96
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL 96
Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma 94
Peripheral nervous system involvement in lymphomas 93
Ibrutinib in relapsed hairy cell leukemia variant: a case report and review of the literature 93
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12 91
Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies 91
CLL patients carrying 13q deletion show clinical heterogenity according to IGVH mutational status and CD38 expression 90
Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals 89
A SCORING SYSTEM TO PREDICT THE RISK OF ATRIAL FIBRILLATION IN CHRONIC LYMPHOCYTIC LEUKEMIA 89
New responsibilities for aged kinases in B-lymphomas 86
Increased Survival and Migration of CLL B-Cells in the Presence of Marrow Mesenchymal Stromal Cells: Novel Findings for Microenvironment-Targeted Therapies 84
Incidental lymphomas in surgical pathology: diagnostic clues and clinical-pathological correlations 84
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 71
Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells 70
Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma 70
Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment 68
Nerve Ultrasound abnormalities mirrors the course of VZV sensory-motor radiculoplexopathy 67
Mechanisms of Nerve Damage in Neuropathies Associated with Hematological Diseases: Lesson from Nerve Biopsies 66
B cells from Chronic Lymphocytic Leukemia undergo apoptosis following microtubule depolymerization by nocodazole 65
A case of “double hit” mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib 65
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic Leukemia. A Real‐Life Campus CLL Study 63
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 61
Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia 61
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 58
Genetic Landscape of Ultra-Stable Chronic Lymphocytic Leukemia Patients 57
EFFICACY OF IDELALISIB AND RITUXIMAB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA TREATED OUTSIDE OF CLINICAL TRIALS. A REPORT OF THE GIMEMA WORKING GROUP 57
Leukemic cell from B-CLL patients display heterogeneous response to the anti-apoptotic effect of mesenchymal stromal cells 53
CLL patients with low-risk cytogenetic abnormalities show clinical heterogeneity according to IGVH mutational status and CD38 expression 53
Assessment of the 4-factor score: retrospective analysis of 586 cll patients receiving ibrutinib. A campus cll study 53
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL) 52
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy 52
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials 51
Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: potential relevance of antibody titers in monitoring treatment response 49
Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms 49
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 48
Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases 47
A Case of Hemophagocytic Lymphohistiocytosis Triggered by Disseminated Tuberculosis and Hairy Cell Leukaemia after SARS-CoV2 Infection 42
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL 41
Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study 40
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab 40
Limbic Encephalitis with HU-Antibodies in T-cell Anaplastic Lymphoma. A Case Report 40
Increase of IgA during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia (CLL) patients 39
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia 39
From pathogenesis to personalized treatments of neuropathies in hematological malignancies 38
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 37
Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study 36
From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance 35
A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report 34
TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases 34
Anaemia during venetoclax ramp-up phase: Do not forget unusual causes 31
Waldenström Macroglobulinemia in Very Elderly (≥75-year-old) Patients: A 33-year-retrospective Cohort Study in an Italian University Hospital 30
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies 28
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: a Fondazione Italiana Linfomi real-life experience 28
Glycerophosphoinositol Promotes Apoptosis of Chronic Lymphocytic Leukemia Cells by Enhancing Bax Expression and Activation 28
Response to "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients" 27
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 27
Prediction of outcomes in cll patients treated with ibrutinib: validation of current prognostic models and development of a simplified three-factor model 27
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia 26
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 25
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia 23
[18F]FDG PET/CT and PET/MR in Patients with Adrenal Lymphoma: A Systematic Review of Literature and a Collection of Cases 23
Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies 23
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation 22
Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness 22
Totale 8.105
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.493
article - articoli 40.041
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 64
Totale 80.598
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.007 0 0 0 0 0 78 108 167 156 230 171 97
2020/20211.781 123 110 128 213 52 35 70 139 220 332 216 143
2021/20221.554 77 142 129 122 145 88 86 143 138 41 132 311
2022/20231.072 212 85 32 127 152 106 15 77 113 18 96 39
2023/20241.042 40 92 72 66 71 142 80 62 55 120 120 122
2024/20251.068 38 277 198 142 405 8 0 0 0 0 0 0
Totale 8.712